Insmed Incorporated (NASDAQ:INSM - Get Free Report) CEO William Lewis sold 6,830 shares of the company's stock in a transaction that occurred on Tuesday, April 15th. The shares were sold at an average price of $70.16, for a total value of $479,192.80. Following the transaction, the chief executive officer now directly owns 233,924 shares of the company's stock, valued at $16,412,107.84. This trade represents a 2.84 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
William Lewis also recently made the following trade(s):
- On Monday, March 17th, William Lewis sold 18,750 shares of Insmed stock. The shares were sold at an average price of $77.03, for a total value of $1,444,312.50.
- On Monday, March 3rd, William Lewis sold 18,750 shares of Insmed stock. The shares were sold at an average price of $77.79, for a total value of $1,458,562.50.
- On Tuesday, February 18th, William Lewis sold 18,750 shares of Insmed stock. The stock was sold at an average price of $81.03, for a total transaction of $1,519,312.50.
- On Thursday, February 6th, William Lewis sold 79,350 shares of Insmed stock. The shares were sold at an average price of $80.90, for a total transaction of $6,419,415.00.
- On Monday, February 3rd, William Lewis sold 18,750 shares of Insmed stock. The stock was sold at an average price of $77.94, for a total transaction of $1,461,375.00.
Insmed Trading Down 1.2 %
Shares of NASDAQ:INSM opened at $70.20 on Thursday. The firm has a fifty day moving average of $75.60 and a two-hundred day moving average of $73.60. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. Insmed Incorporated has a 12-month low of $21.92 and a 12-month high of $84.91. The firm has a market capitalization of $12.76 billion, a P/E ratio of -12.56 and a beta of 1.07.
Insmed (NASDAQ:INSM - Get Free Report) last released its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.15). Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The firm had revenue of $104.44 million for the quarter, compared to analyst estimates of $102.31 million. On average, equities analysts expect that Insmed Incorporated will post -4.56 EPS for the current fiscal year.
Institutional Trading of Insmed
Several large investors have recently added to or reduced their stakes in the business. Elequin Capital LP bought a new stake in Insmed in the fourth quarter worth $28,000. Steward Partners Investment Advisory LLC lifted its position in shares of Insmed by 65.2% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company's stock worth $29,000 after buying an additional 163 shares during the last quarter. V Square Quantitative Management LLC boosted its stake in shares of Insmed by 60.3% during the 4th quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company's stock worth $45,000 after acquiring an additional 248 shares in the last quarter. Spire Wealth Management acquired a new position in shares of Insmed during the 4th quarter valued at about $47,000. Finally, NBC Securities Inc. bought a new position in shares of Insmed in the 1st quarter valued at approximately $49,000.
Wall Street Analysts Forecast Growth
INSM has been the subject of several analyst reports. Morgan Stanley boosted their price objective on Insmed from $85.00 to $90.00 and gave the stock an "overweight" rating in a research report on Thursday, February 6th. Guggenheim reissued a "buy" rating and issued a $101.00 price target on shares of Insmed in a research note on Tuesday, February 25th. Stifel Nicolaus lowered their price target on Insmed from $97.00 to $96.00 and set a "buy" rating on the stock in a report on Friday, February 21st. JPMorgan Chase & Co. upped their price objective on shares of Insmed from $83.00 to $92.00 and gave the stock an "overweight" rating in a report on Friday, February 7th. Finally, Royal Bank of Canada reiterated an "outperform" rating and issued a $100.00 price objective on shares of Insmed in a report on Wednesday, March 19th. One investment analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $94.00.
View Our Latest Stock Report on INSM
About Insmed
(
Get Free Report)
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
